EG27095A - ACE2 polypeptide - Google Patents

ACE2 polypeptide

Info

Publication number: EG27095A
Authority: EG; Egypt
Prior art keywords: ace2 polypeptide; ace2; polypeptide
Prior art date: 2007-06-12

Application number

EG2009121812A

Other languages

English (en)

Inventor

Manfred Schuster

Hans Loibner

Evelyne Janzek-Hawlat

Bernhard Peball

Stefan Stranner

Bettina Wagner

Robert Weik

Original Assignee

Apeiron Biologics Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-06-12

Filing date

2009-12-10

Publication date

2015-05-28

2008-04-08 Priority claimed from EP08450052A external-priority patent/EP2108695A1/fr

2009-12-10 Application filed by Apeiron Biologics Ag filed Critical Apeiron Biologics Ag

2015-05-28 Application granted granted Critical

2015-05-28 Publication of EG27095A publication Critical patent/EG27095A/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/485—Exopeptidases (3.4.11-3.4.19)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/17—Metallocarboxypeptidases (3.4.17)
- C12Y304/17023—Angiotensin-converting enzyme 2 (3.4.17.23)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Biochemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
General Engineering & Computer Science (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Cardiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Toxicology (AREA)
Cell Biology (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

EG2009121812A 2007-06-12 2009-12-10 ACE2 polypeptide EG27095A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
AT0091307A AT505262A1 (de)	2007-06-12	2007-06-12	Rekombinantes ace2 polypeptid
EP08450052A EP2108695A1 (fr)	2008-04-08	2008-04-08	Polypeptide Ace2
PCT/AT2008/000211 WO2008151347A1 (fr)	2007-06-12	2008-06-12	Polypeptide ace2

Publications (1)

Publication Number	Publication Date
EG27095A true EG27095A (en)	2015-05-28

Family

ID=39720296

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EG2009121812A EG27095A (en)	2007-06-12	2009-12-10	ACE2 polypeptide

Country Status (35)

Country	Link
US (3)	US8586319B2 (fr)
EP (3)	EP3375872A1 (fr)
JP (1)	JP5731193B2 (fr)
KR (2)	KR101682240B1 (fr)
CN (2)	CN104450654A (fr)
AT (1)	AT505262A1 (fr)
AU (1)	AU2008261591B2 (fr)
BR (1)	BRPI0813942B8 (fr)
CA (1)	CA2692854C (fr)
CO (1)	CO6270265A2 (fr)
CR (1)	CR11213A (fr)
CY (2)	CY1116873T1 (fr)
DK (2)	DK2543724T3 (fr)
DO (1)	DOP2009000282A (fr)
EA (1)	EA027399B1 (fr)
EG (1)	EG27095A (fr)
ES (2)	ES2550390T3 (fr)
HK (1)	HK1255493A1 (fr)
HR (2)	HRP20151120T1 (fr)
HU (2)	HUE037877T2 (fr)
IL (1)	IL202653B (fr)
LT (1)	LT2543724T (fr)
MA (1)	MA31472B1 (fr)
MX (1)	MX2009013472A (fr)
MY (1)	MY180672A (fr)
NO (1)	NO2543724T3 (fr)
NZ (1)	NZ581704A (fr)
PL (2)	PL2543724T3 (fr)
PT (2)	PT2155871E (fr)
RS (2)	RS57292B1 (fr)
SI (2)	SI2543724T1 (fr)
TR (1)	TR201808117T4 (fr)
UA (1)	UA106869C2 (fr)
WO (1)	WO2008151347A1 (fr)
ZA (1)	ZA200908751B (fr)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20140113860A1 (en)	2006-02-03	2014-04-24	Prolor Biotech Ltd.	Long-acting polypeptides and methods of producing and administering same
US8048849B2 (en)	2006-02-03	2011-11-01	Modigene, Inc.	Long-acting polypeptides and methods of producing same
US9458444B2 (en)	2006-02-03	2016-10-04	Opko Biologics Ltd.	Long-acting coagulation factors and methods of producing same
US9249407B2 (en)	2006-02-03	2016-02-02	Opko Biologics Ltd.	Long-acting coagulation factors and methods of producing same
US8946155B2 (en)	2006-02-03	2015-02-03	Opko Biologics Ltd.	Long-acting polypeptides and methods of producing and administering same
US10221228B2 (en)	2006-02-03	2019-03-05	Opko Biologics Ltd.	Long-acting polypeptides and methods of producing and administering same
US20150038413A1 (en)	2006-02-03	2015-02-05	Opko Biologics Ltd.	Long-acting polypeptides and methods of producing and administering same
US10351615B2 (en)	2006-02-03	2019-07-16	Opko Biologics Ltd.	Methods of treatment with long-acting growth hormone
AT505262A1 (de) *	2007-06-12	2008-12-15	Apeiron Biolog Forschungs Und	Rekombinantes ace2 polypeptid
EP2077119A1 (fr) *	2007-12-21	2009-07-08	Apeiron Biologics Forschungs- und Entwicklungsgesellschaft M.B.H.	Traitement de fibroses et de maladies du foie
AT506632A1 (de) *	2008-04-09	2009-10-15	Apeiron Biolog Forschungs Und	Behandlung von tumorerkrankungen
US9663778B2 (en)	2009-07-09	2017-05-30	OPKO Biologies Ltd.	Long-acting coagulation factors and methods of producing same
US12203113B2 (en)	2009-07-09	2025-01-21	Opko Biologics Ltd.	Long-acting coagulation factors and methods of producing same
PE20142405A1 (es)	2012-04-19	2015-01-25	Opko Biolog Ltd	Variantes de oxintomodulina de accion prolongada y metodos de produccion de las mismas
BR112015002091A2 (pt)	2012-08-02	2017-12-12	Hoffmann La Roche	método para a produção de um polipeptídeo, polipeptídeo, uso de um polipeptídeo e composição
EP2922867B1 (fr)	2012-11-20	2021-07-21	OPKO Biologics Ltd.	Procédé d'augmentation du volume hydrodynamique de polypeptides par la fixation à des peptides carboxy terminaux de gonadotrophine
US9757433B2 (en)	2013-01-14	2017-09-12	Apeiron Biologicals AG	Modified ACE2 polypeptides
US20150158926A1 (en)	2013-10-21	2015-06-11	Opko Biologics, Ltd.	Long-acting polypeptides and methods of producing and administering same
PH12017501089B1 (en)	2014-12-10	2022-06-22	Opko Biologics Ltd	Methods of producing long acting ctp-modified growth hormone polypeptides
AU2016280867B2 (en)	2015-06-19	2020-02-27	Opko Biologics Ltd.	Long-acting coagulation factors and methods of producing same
KR102618424B1 (ko)	2016-07-11	2023-12-26	옵코 바이오로직스 리미티드	지속성 응고 인자 vii 및 그 제조 방법
US11518788B2 (en) *	2020-07-10	2022-12-06	Avirus, Inc.	Methods and compositions for treating and preventing viral infection
BR112022014552A2 (pt) *	2020-01-23	2022-10-25	Avirus Inc	Polipeptídeo recombinante, composição farmacêutica, método de prevenção ou tratamento de uma infecção viral em um indivíduo que necessita do mesmo, molécula de rna, composição terapêutica, sistema de expressão, polipeptídeo recombinante para tratar infecção por sars-cov-2 e polinucleotídeo que codifica o polipeptídeo recombinante
WO2021190980A1 (fr)	2020-03-22	2021-09-30	Quadrucept Bio Limited	Multimères pour l'évolution d'une souche virale
EP3884957A1 (fr)	2020-03-26	2021-09-29	The University of British Columbia	Procédés de traitement de virus et procédés de criblage de réactif anti-virus à l'aide d'organoïdes
US20230293647A1 (en) *	2020-04-09	2023-09-21	Autolus Limited	Polypeptide
WO2021217120A2 (fr) *	2020-04-24	2021-10-28	Administrators Of The Tulane Educational Fund	Compositions et procédés visant à prévenir ou réduire les effets d'infections par des coronavirus qui se lient au domaine extracellulaire du récepteur ace2
CN113667016A (zh) *	2020-05-15	2021-11-19	普米斯生物技术(珠海)有限公司	一种构建冠状病毒抗体的平台
WO2021247675A1 (fr)	2020-06-02	2021-12-09	Ngm Biopharmaceuticals, Inc.	Agents liant les coronavirus et leurs utilisations
DE102020207224A1 (de)	2020-06-09	2021-12-09	Christoph Karle	Protein oder Peptid, insbesondere zur Prophylaxe und/oder Behandlung einer durch Coronaviren, insbesondere SARS-CoV-2-Viren, hervorgerufenen Infektion oder Infektionskrankheit und/oder einer Folgekrankheit davon
AU2021297998A1 (en) *	2020-06-25	2022-12-15	Gliknik Inc.	ACE2-Fc fusion proteins and methods of use
WO2022008642A1 (fr)	2020-07-08	2022-01-13	Apeiron Biologics Ag	Traitement d'une infection par le sras-cov-2 avec une combinaison de cibles
CN116348492A (zh) *	2020-07-10	2023-06-27	生物分子控股有限责任公司	四面体抗体
WO2022037699A1 (fr) *	2020-08-21	2022-02-24	Westlake University	Oligomères d'ace2 modifiés et leurs utilisations
KR102725210B1 (ko) *	2020-10-05	2024-11-04	한양대학교 산학협력단	안정화된 Ace2 변이체, 이를 이용한 Ace2-Fc 융합단백질 및 COVID-19 예방 또는 치료용 약학 조성물
CN112280764A (zh) *	2020-11-18	2021-01-29	通用生物系统（安徽）有限公司	一种新冠重组ace2蛋白在哺乳动物细胞中的生产方法
EP4011387A1 (fr)	2020-12-11	2022-06-15	IMBA-Institut für Molekulare Biotechnologie GmbH	Neutralisation supérieure du sars-cov-2 par la conversion de l'enzyme 2 de l'angiotensine humaine déglycosylée
US20220226489A1 (en)	2021-01-20	2022-07-21	Singh Biotechnology, Llc	Therapeutics directed against coronavirus
WO2022184659A1 (fr)	2021-03-01	2022-09-09	Quadrucept Bio Limited	Domaines d'anticorps et multimères
WO2022207918A1 (fr)	2021-04-02	2022-10-06	Apeiron Biologics Ag	Thérapie anti-covid-19
EP4387732A4 (fr)	2021-08-19	2025-09-03	Phenom Pharmaceuticals Inc	Compositions et méthodes pour le traitement du sars-cov-2
CN113897346A (zh) *	2021-09-16	2022-01-07	四川大学	能够提高与SARS-CoV-2 S蛋白亲和力的ACE2突变组合及应用
KR102834587B1 (ko) *	2021-09-16	2025-07-17	인에이블앱 주식회사	안지오텐신전환효소 2 수용체 및 이의 용도
DE102023118690A1 (de)	2023-07-14	2025-01-16	Christoph Karle	Protein oder Peptid, insbesondere zur Prophylaxe und/oder Behandlung einer Infektion und/oder Infektionskrankheit und/oder einer Folgeerkrankung davon

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6989363B1 (en) *	1997-12-11	2006-01-24	Millennium Pharmaceuticals, Inc.	Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
US6610497B1 (en)	1997-12-11	2003-08-26	Millennium Pharmaceuticals, Inc.	Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therefor
US6194556B1 (en) *	1997-12-11	2001-02-27	Millennium Pharmaceuticals, Inc.	Angiotensin converting enzyme homolog and therapeutic and diagnostic uses therfor
ATE415175T1 (de)	2002-06-19	2008-12-15	Univ Health Network	Ace2-aktivierung zur behandlung von herz, lungen, und nierenkrankheit und bluthochdruck
WO2004023270A2 (fr)	2002-09-09	2004-03-18	Millenium Pharmaceuticals, Inc.	Structure cristalline de la carboxypeptidase liee a l'enzyme convertissant l'angiotensine
EP1723962A1 (fr) *	2005-05-19	2006-11-22	IMBA-Institut für Molekulare Biotechnologie GmbH	Utilisation des inhibiteurs du système de rénine-angiotensine pour le traitement des lesions poumonaires.
AT504443B1 (de) *	2006-10-19	2008-11-15	Apeiron Biolog Forschungs Und	Verfahren zur bestimmung der aktivität von ace2
AT505262A1 (de) *	2007-06-12	2008-12-15	Apeiron Biolog Forschungs Und	Rekombinantes ace2 polypeptid
EP2108695A1 (fr)	2008-04-08	2009-10-14	Apeiron Biologics Forschungs- und Entwicklungsgesellschaft M.B.H.	Polypeptide Ace2
AT506258A1 (de) *	2007-12-18	2009-07-15	Apeiron Biolog Forschungs Und	Behandlung inflammatorischer krankheiten
AT506632A1 (de) *	2008-04-09	2009-10-15	Apeiron Biolog Forschungs Und	Behandlung von tumorerkrankungen

2007
- 2007-06-12 AT AT0091307A patent/AT505262A1/de not_active Application Discontinuation
2008
- 2008-06-12 ES ES08756821.8T patent/ES2550390T3/es active Active
- 2008-06-12 AU AU2008261591A patent/AU2008261591B2/en active Active
- 2008-06-12 PT PT87568218T patent/PT2155871E/pt unknown
- 2008-06-12 CN CN201410412672.3A patent/CN104450654A/zh active Pending
- 2008-06-12 MY MYPI20095316A patent/MY180672A/en unknown
- 2008-06-12 RS RS20180677A patent/RS57292B1/sr unknown
- 2008-06-12 KR KR1020097027569A patent/KR101682240B1/ko active Active
- 2008-06-12 EP EP18161541.0A patent/EP3375872A1/fr not_active Withdrawn
- 2008-06-12 MX MX2009013472A patent/MX2009013472A/es active IP Right Grant
- 2008-06-12 JP JP2010511445A patent/JP5731193B2/ja active Active
- 2008-06-12 NZ NZ581704A patent/NZ581704A/en unknown
- 2008-06-12 HU HUE12165189A patent/HUE037877T2/hu unknown
- 2008-06-12 RS RS20150709A patent/RS54340B1/sr unknown
- 2008-06-12 PL PL12165189T patent/PL2543724T3/pl unknown
- 2008-06-12 NO NO12165189A patent/NO2543724T3/no unknown
- 2008-06-12 TR TR2018/08117T patent/TR201808117T4/tr unknown
- 2008-06-12 BR BRPI0813942A patent/BRPI0813942B8/pt active IP Right Grant
- 2008-06-12 SI SI200831961T patent/SI2543724T1/en unknown
- 2008-06-12 SI SI200831514T patent/SI2155871T1/sl unknown
- 2008-06-12 DK DK12165189.7T patent/DK2543724T3/en active
- 2008-06-12 US US12/664,641 patent/US8586319B2/en active Active
- 2008-06-12 EA EA201000002A patent/EA027399B1/ru unknown
- 2008-06-12 CA CA2692854A patent/CA2692854C/fr active Active
- 2008-06-12 LT LTEP12165189.7T patent/LT2543724T/lt unknown
- 2008-06-12 PT PT121651897T patent/PT2543724T/pt unknown
- 2008-06-12 ES ES12165189.7T patent/ES2670938T3/es active Active
- 2008-06-12 WO PCT/AT2008/000211 patent/WO2008151347A1/fr not_active Ceased
- 2008-06-12 CN CN200880100650A patent/CN101796183A/zh active Pending
- 2008-06-12 HU HUE08756821A patent/HUE028012T2/en unknown
- 2008-06-12 KR KR1020167011786A patent/KR20160054045A/ko not_active Ceased
- 2008-06-12 EP EP08756821.8A patent/EP2155871B1/fr active Active
- 2008-06-12 DK DK08756821.8T patent/DK2155871T3/en active
- 2008-06-12 PL PL08756821T patent/PL2155871T3/pl unknown
- 2008-06-12 UA UAA200912888A patent/UA106869C2/uk unknown
- 2008-06-12 EP EP12165189.7A patent/EP2543724B1/fr active Active
- 2008-06-12 HR HRP20151120TT patent/HRP20151120T1/hr unknown
2009
- 2009-01-01 ZA ZA200908751A patent/ZA200908751B/xx unknown
- 2009-12-10 IL IL202653A patent/IL202653B/en active IP Right Grant
- 2009-12-10 EG EG2009121812A patent/EG27095A/xx active
- 2009-12-11 DO DO2009000282A patent/DOP2009000282A/es unknown
- 2009-12-30 MA MA32464A patent/MA31472B1/fr unknown
2010
- 2010-01-08 CO CO10001879A patent/CO6270265A2/es not_active Application Discontinuation
- 2010-01-12 CR CR11213A patent/CR11213A/es unknown
- 2010-04-28 HK HK18114676.2A patent/HK1255493A1/zh unknown
2013
- 2013-09-13 US US14/026,887 patent/US20140099297A1/en not_active Abandoned
2015
- 2015-10-26 CY CY20151100955T patent/CY1116873T1/el unknown
2017
- 2017-12-06 US US15/833,243 patent/US10716833B2/en active Active
2018
- 2018-05-23 CY CY20181100549T patent/CY1120426T1/el unknown
- 2018-05-30 HR HRP20180856TT patent/HRP20180856T1/hr unknown

Also Published As

Publication number	Publication date
KR20100040809A (ko)	2010-04-21
HRP20151120T1 (xx)	2015-11-20
KR101682240B1 (ko)	2016-12-06
AU2008261591B2 (en)	2014-08-07
HUE028012T2 (en)	2016-11-28
DOP2009000282A (es)	2010-03-31
TR201808117T4 (tr)	2018-07-23
SI2155871T1 (sl)	2015-11-30
HUE037877T2 (hu)	2018-09-28
BRPI0813942B1 (pt)	2019-08-20
EP2155871B1 (fr)	2015-08-12
IL202653B (en)	2018-01-31
EP2543724A3 (fr)	2013-02-20
BRPI0813942A2 (pt)	2014-12-30
AU2008261591A1 (en)	2008-12-18
CO6270265A2 (es)	2011-04-20
US8586319B2 (en)	2013-11-19
HRP20180856T1 (hr)	2018-08-24
ES2550390T3 (es)	2015-11-06
RS57292B1 (sr)	2018-08-31
RS54340B1 (sr)	2016-02-29
EP2543724B1 (fr)	2018-03-21
JP2011519264A (ja)	2011-07-07
ES2670938T3 (es)	2018-06-04
PL2155871T3 (pl)	2015-12-31
KR20160054045A (ko)	2016-05-13
ZA200908751B (en)	2010-07-28
EP2155871A1 (fr)	2010-02-24
PL2543724T3 (pl)	2018-08-31
UA106869C2 (uk)	2014-10-27
CA2692854C (fr)	2017-07-04
CY1116873T1 (el)	2017-04-05
CR11213A (es)	2010-04-20
NZ581704A (en)	2012-05-25
DK2543724T3 (en)	2018-05-28
US20100310546A1 (en)	2010-12-09
PT2543724T (pt)	2018-06-11
CA2692854A1 (fr)	2008-12-18
EA201000002A1 (ru)	2010-08-30
CN101796183A (zh)	2010-08-04
LT2543724T (lt)	2018-06-25
NO2543724T3 (fr)	2018-08-18
IL202653A0 (en)	2011-08-01
CN104450654A (zh)	2015-03-25
BRPI0813942B8 (pt)	2021-05-25
MA31472B1 (fr)	2010-06-01
US20180289779A1 (en)	2018-10-11
WO2008151347A1 (fr)	2008-12-18
HK1136602A1 (en)	2010-07-02
CY1120426T1 (el)	2019-07-10
SI2543724T1 (en)	2018-07-31
MX2009013472A (es)	2010-06-25
EA027399B1 (ru)	2017-07-31
MY180672A (en)	2020-12-05
HK1255493A1 (zh)	2019-08-16
AT505262A1 (de)	2008-12-15
EP2543724A2 (fr)	2013-01-09
DK2155871T3 (en)	2015-11-09
PT2155871E (pt)	2015-10-26
US10716833B2 (en)	2020-07-21
EP3375872A1 (fr)	2018-09-19
JP5731193B2 (ja)	2015-06-10
US20140099297A1 (en)	2014-04-10

Publication	Publication Date	Title
EG27095A (en)	2015-05-28	ACE2 polypeptide
ZA200810738B (en)	2018-11-28	Polypeptide
DE602007008470D1 (en)	2010-09-23	Off
GB0721686D0 (en)	2007-12-12	Polypeptides
ZA201000283B (en)	2011-06-29	Reinigung pegylierter polypeptide
GB0723712D0 (en)	2008-01-16	Peptides
EP2123666A4 (fr)	2011-01-05	Peptide
GB0723387D0 (en)	2008-01-09	Improved dehumldifier
GB0704693D0 (en)	2007-04-18	Multi-plough
GB0809659D0 (en)	2008-07-02	Polypeptides
GB0703945D0 (en)	2007-04-11	Peptide
GB0712302D0 (en)	2007-08-01	Chrondroitinase polypeptides
GB0713585D0 (en)	2007-08-22	Equivalent
IL197675A0 (en)	2009-12-24	Peptides
GB0703927D0 (en)	2007-04-11	Fuel
KG1098C1 (en)	2008-11-29	Towel-drying construction
GB0705251D0 (en)	2007-04-25	Peptides
GB0707626D0 (en)	2007-05-30	Peptides
GB0705115D0 (en)	2007-04-25	Peptides
GB0721702D0 (en)	2007-12-12	Hydrogienic globaltechnology limited
GB0609691D0 (en)	2006-06-28	Corcost 5a
GB0706942D0 (en)	2007-05-16	Fuel store-2
GB0717492D0 (en)	2007-10-24	Turn case
GB0705748D0 (en)	2007-05-02	Finally finally
GB0713330D0 (en)	2007-08-22	Richochet III